Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
The companies will split development costs and future profits evenly as the pact adds four early-stage antibody drugs targeting immunological diseases.
- On Thursday, Sanofi and Regeneron Pharmaceuticals announced an expanded partnership including a $1 billion upfront payment and up to $7 billion in milestone payments to develop four new antibody drugs.
- The four antibody drugs target the same type 2 inflammation pathways as Dupixent, with REGN20423 currently in early-stage testing for atopic dermatitis and three others expected to begin clinical testing in 2027.
- Regeneron will lead research and development while Sanofi spearheads global sales efforts; the companies will share costs equally and split future Profits from these potential products.
- The agreement marks an early success for CEO Belen Garijo, who took Sanofi's top role in May; the deal also settles litigation and addresses investor concerns regarding Dupixent's patent expiration.
- Jefferies analyst Michael Leuchten described the expansion as a positive signal of Sanofi's proactive focus on addressing key investor uncertainties and demonstrating speed of progress in immunology.
24 Articles
24 Articles
By announcing on Thursday an important collaboration agreement with Regeneron, Sanofi is getting hold of antibodies to take over his flagship drug, the Dupixent, whose patent expires in 2031.
DECRYPTAGE - The French laboratory, which has to replenish its portfolio of medicines, spends up to €8 billion.
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT. Under the agreement, Regeneron will contribute four long-acting, fully hu
Pharmacists Sanofi and Regeneron have concluded an agreement to expand their strategic alliance in the co-development and global marketing of new immunology drugs, in a transaction with a potential value of up to US$ 8 billion for the American partner. Exclusive material for subscribers. To have full access, access the link of the material and register.
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
